

DETAILED ACTION

Applicant's election with traverse of Group 2 in the reply filed on 01/12/2009 is acknowledged. The traversal is on the ground(s) that the Examiner did not provide appropriate time for response to alleged indefiniteness and use of non-statutory claim language. Further applicant requests (see page 25, second paragraph) that the Examiner provide a second restriction requirement listing all the claims into restriction. This request was confirmed with attorney for the applicant Eric Sinn on 03/04/2009. See Interview Summary. Accordingly, the Restriction/Requirement is recast as follows:

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-6, 14-16 drawn to compounds of formula I wherein Ar is phenyl or naphthalenyl and A is not 4-oxazolyl.

Group 1-P, claim(s) 7-8, drawn to process of making compounds of Group 1.

Group 12, claim(s) 17-21, drawn to methods of treating various diseases using compounds of Group 1. If this group is elected further restriction based on the disease being treated would be necessary.

Group 7, claim(s) 16, drawn to pharmaceutical compositions containing compounds of Group 1 and additional ingredient. Further restriction based on the additional ingredient is anticipated if this group is elected.

Groups 14, claim(s) 22, drawn to preparation of medicine suitable for treatment of diseases by the use of compound of Group 1.

Group 2, claim(s) 1-6, 14-16 drawn to compounds of formula I wherein Ar is single or fused divalent aromatic other than compounds of Group 1. Election of single disclosed species is required.

Group 3, claim(s) 1-6, 14-16 drawn to compounds of formula I wherein Ar is single or fused divalent heteroaromatic. Election of single disclosed species is required.

Group 4, claim(s) 1-6, drawn to compounds of formula I wherein Ar is single or fused divalent heterocyclic. Election of single disclosed species is required.

Group 2-P, claim(s) 7-8, drawn to process of making compounds of Group 2.

Group 3-P, claim(s) 7-8, drawn to process of making compounds of Group 3.

Group 4-P, claim(s) 7-8, drawn to process of making compounds of Group 4.

Group 12, claim(s) 17-21, drawn to methods of treating various diseases using compounds of Group 2. If this group is elected further restriction based on the disease being treated would be necessary.

Group 12, claim(s) 17-21, drawn to methods of treating various diseases using compounds of Group 3. If this group is elected further restriction based on the disease being treated would be necessary.

Group 12, claim(s) 17-21, drawn to methods of treating various diseases using compounds of Group 4. If this group is elected further restriction based on the disease being treated would be necessary.

Group 8, claim(s) 16, drawn to pharmaceutical compositions containing compounds of Group 2 and additional ingredient. Further restriction based on the additional ingredient is anticipated if this group is elected.

Group 9, claim(s) 16, drawn to pharmaceutical compositions containing compounds of Group 3 and additional ingredient. Further restriction based on the additional ingredient is anticipated if this group is elected.

Group 10, claim(s) 16, drawn to pharmaceutical compositions containing compounds of Group 4 and additional ingredient. Further restriction based on the additional ingredient is anticipated if this group is elected.

Groups 15, claim(s) 22, drawn to preparation of medicine suitable for treatment of diseases by the use of compound of Group 2.

Groups 16, claim(s) 22, drawn to preparation of medicine suitable for treatment of diseases by the use of compound of Group 3.

Groups 17, claim(s) 22, drawn to preparation of medicine suitable for treatment of diseases by the use of compound of Group 4.

Group 5, claim(s) 9-12, 23, 24 drawn to compounds of formula IIIa.


Group 6, claim(s) 13, drawn to process of making compounds of Group 5.

Group 11, claim(s) 25, drawn to pharmaceutical compositions containing compounds of Group 5 and additional ingredient. Further restriction based on the additional ingredient is anticipated if this group is elected.

Group 13, claim(s) 26-29, drawn to methods of treating various diseases using compounds of Group 5. If this group is elected further restriction based on the disease being treated would be necessary.

Groups 18, claim(s) 30, drawn to preparation of medicine suitable for treatment of diseases by the use of compound of Group 5.

The inventions listed as Groups 1-17 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: structural moiety common to all the groups is not a contribution over the prior art. See applicant cited,



prior art WO 01/40170 which discloses

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded of *In re Zletz*, 13 USPQ2d 1320, 1322. "An essential purpose of patent examination is to fashion claims that are precise, clear, correct and unambiguous." The specification and claims are replete with typographical errors. The

claims are drawn to vague definition of various groups. Terms such as 'analogs' render the mete and bounds of the claims unclear. The point of attachment of one variable to another in the formula is unclear. The variable Ar group has to have two attachments, thus it can not be phenyl. Non-statutory language 'use of' without setting forth the steps involved in the process would necessitate rejections under U.S.C. 101.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product

are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S. CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached on 8.30 AM - 4.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571 0272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nizal S. Chandrakumar

/D. Margaret Seaman/
Primary Examiner, Art Unit 1625